These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2242318)

  • 1. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.
    Boudailliez BR; Pautard BJ; Sebert JL; Kremp O; Piussan CX
    Pediatr Nephrol; 1990 Sep; 4(5):510-1. PubMed ID: 2242318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
    Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
    Bone; 1986; 7(4):247-53. PubMed ID: 3768203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.
    Varache N; Audran M; Clochon P; Lortholary A; Bouachour G; Alquier P; Basle MF
    Clin Rheumatol; 1991 Sep; 10(3):328-32. PubMed ID: 1790647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH; Alzaid AA; Gardner MD; Boyle IT
    Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
    Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
    Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy.
    De Schepper J; de Pont S; Smitz J; De Coster D; Schots R; Otten J
    Eur J Pediatr; 1999 Sep; 158(9):765-6. PubMed ID: 10485313
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
    Tan TT; Alzaid AA; Sutcliffe N; Gardner MD; Thomson JA; Boyle IT
    Postgrad Med J; 1988 Mar; 64(749):224-7. PubMed ID: 3174541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
    Grutters JC; Hermus AR; de Mulder PH; Beex LV
    Breast Cancer Res Treat; 1993; 25(3):277-81. PubMed ID: 8369528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
    Sawyer N; Newstead C; Drummond A; Cunningham J
    Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
    McIntyre HD; Cameron DP; Urquhart SM; Davies WE
    Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ; Borkowski A; Cleeren A; Bijvoet OL
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
    Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT
    Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment.
    Yap AS; Hockings GI; Fleming SJ; Khafagi FA
    Clin Nephrol; 1990 Nov; 34(5):225-9. PubMed ID: 2268980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children.
    Schmid I; Stachel D; Schön C; Bauer M; Haas RJ
    Klin Padiatr; 2001; 213(1):30-4. PubMed ID: 11225473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate).
    Oliveri B; Mastaglia SR; Mautalen C; Gravano JC; Pardo Argerich L
    Acta Paediatr; 2004 Jul; 93(7):1002-3. PubMed ID: 15303821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.